Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
BMS Gains Second Indication For Krazati – One More Than Amgen’s Lumakras
CRC Added To NSCLC, Both Second-Line Or Later
25 Jun 2024
•
By
Mandy Jackson
Krazati is the first KRAS G12C inhibitor approved in colorectal cancer • Source: Shutterstock
More from New Products
More from Scrip